ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2236

Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study

Gihyun Myung1, Winnie Nelson2 and Maureen A. McMahon3, 1Division of Rheumatology/Department of Internal Medicine, University of California-Los Angeles, Los Angeles, CA, 2Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ, 3University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: corticosteroids, dermatomyositis, polymyositis, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Health Services Research - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Repository corticotropin injection (RCI) may produce anti-inflammatory and immune-modulatory effects. This study examined the demographics of those who used RCI and the trends in medication use, specifically prednisone, after RCI initiation.

Methods: This retrospective analysis of the Symphony Health Solutions Patient Transactional Dataset from 2008 to 2015 included patients with at least 1 claim for RA, SLE, or DM/PM, and any use of RCI. Patients with claims for non-rheumatologic conditions that may also be treated by RCI, namely, multiple sclerosis and proteinuria, were excluded. Demographics, patterns of RCI use, and concomitant medications (corticosteroids [CS], biologics, NSAIDs, and DMARDs) were reported. Patients were followed for concomitant medication use from 2 years prior to and 1 year after RCI initiation. Paired two-tailed t-test was used to calculate the p values for the use of each drug class before/after RCI initiation.

Results: Out of 2.7 million rheumatologic patients in the database over 6 years, there were 2,749 patients who used RCI – 1269 RA patients, 874 SLE patients, and 606 with DM/PM (Table 1). SLE patients were younger than RA and DM/PM patients, and most of the patients were female for all 3 conditions. Majority of patients received 80U of RCI twice weekly. The study identified 504 RA, 322 SLE, and 222 DM/PM patients with sufficient follow up time to evaluate concomitant medication use. For all 3 conditions, the proportions of patients who used any CS were significantly lower after RCI initiation: reduced from 67% pre-index to 54% post-index for RA, from 73% to 58% for SLE, and from 76% to 58% for DM/PM (p < 0.05 for all comparisons, Figure 1). Proportions of patients on biologics and DMARDs were also significantly lowered after RCI initiation. In Figure 2, among patients who had taken CS consistently 24 weeks before RCI initiation, dose reductions were statistically significant for RA (28%), and trended lower without statistical significance for SLE (25%) and DM/PM (25%). Limitation of the retrospective analysis include uncertainties in diagnosis, medication use, and factors influencing medication changes.

Conclusion: This claims-based study of patients with RA, SLE, and DM/PM indicated that RCI use may be associated with significant reductions in CS requirements.

 

 

   


Disclosure: G. Myung, None; W. Nelson, Mallinckrodt Pharmaceuticals, 3,Mallinckrodt Pharmaceuticals, 1; M. A. McMahon, None.

To cite this abstract in AMA style:

Myung G, Nelson W, McMahon MA. Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/effects-of-repository-corticotropin-injection-on-medication-use-in-patients-with-rheumatologic-conditions-a-claims-data-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-repository-corticotropin-injection-on-medication-use-in-patients-with-rheumatologic-conditions-a-claims-data-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology